ABSTRACT
The Mediterranean dietary pattern has been linked with reduced cardiovascular disease incidence and mortality. Components of the Mediterranean diet associated with better cardiovascular health include low consumption of meat and meat products, moderate consumption of ethanol (mostly from wine), and high consumption of vegetables, fruits, nuts, legumes, fish, and olive oil. Increasing evidence indicates that the synergy among these components results in beneficial changes in intermediate pathways of cardiometabolic risk, such as lipids, insulin sensitivity, oxidative stress, inflammation, and vasoreactivity. As a result, consumption of a Mediterranean dietary pattern favorably affects numerous cardiovascular disease risk factors, such as dyslipidemia, hypertension, metabolic syndrome, and diabetes. Moreover, strong evidence links this dietary pattern with reduced cardiovascular disease incidence, reoccurrence, and mortality. This review evaluates the current evidence behind the cardioprotective effects of a Mediterranean dietary pattern.
Subject(s)
Cardiovascular Diseases/prevention & control , Diet, Mediterranean , Animals , Cardiovascular Diseases/epidemiology , Cholesterol , Dairy Products , Diabetes Mellitus , Dietary Proteins , Endothelium, Vascular , Female , Humans , Hypertension , Insulin Resistance , Life Style , Lipoproteins , Male , Metabolic Syndrome , Nuts , Olive Oil , Oxidative Stress , Risk Factors , Spices , Vascular Stiffness , WineABSTRACT
In HIV-infected patients, central nervous system (CNS) aspergillosis is rare. Historically, the outcome of such infections has been almost invariably fatal. We report a case involving an AIDS patient with an Aspergillus fumigatus brain abscess who survived for longer than 10 months after surgical drainage and therapy with voriconazole.
Subject(s)
Acquired Immunodeficiency Syndrome/complications , Aspergillus fumigatus/isolation & purification , Neuroaspergillosis/diagnosis , Adult , Antifungal Agents/therapeutic use , Brain/pathology , Head/diagnostic imaging , Humans , Male , Neuroaspergillosis/drug therapy , Neuroaspergillosis/surgery , Pyrimidines/therapeutic use , Radiography , Survival , Time Factors , Treatment Outcome , Triazoles/therapeutic use , VoriconazoleABSTRACT
OBJECTIVES: This study sought to examine the expression and activity of the calcium-dependent nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) in human atherosclerotic coronary arteries. BACKGROUND: The NOX-based NADPH oxidases are major sources of reactive oxygen species (ROS) in human vessels. Several NOX homologues have been identified, but their relative contribution to vascular ROS production in coronary artery disease (CAD) is unclear; NOX5 is a unique homolog in that it is calcium dependent and thus could be activated by vasoconstrictor hormones. Its presence has not yet been studied in human vessels. METHODS: Coronary arteries from patients undergoing cardiac transplantation with CAD or without CAD were studied; NOX5 was quantified and visualized using Western blotting, immunofluorescence, and quantitative real-time polymerase chain reaction. Calcium-dependent NADPH oxidase activity, corresponding greatly to NOX5 activity, was measured by electron paramagnetic resonance. RESULTS: Both Western blotting and quantitative real-time polymerase chain reaction indicated a marked increase in NOX5 protein and messenger ribonucleic acid (mRNA) in CAD versus non-CAD vessels. Calcium-dependent NADPH-driven production of ROS in vascular membranes, reflecting NOX5 activity, was increased 7-fold in CAD and correlated significantly with NOX5 mRNA levels among subjects. Immunofluorescence showed that NOX5 was expressed in the endothelium in the early lesions and in vascular smooth muscle cells in the advanced coronary lesions. CONCLUSIONS: These studies identify NOX5 as a novel, calcium-dependent source of ROS in atherosclerosis.
Subject(s)
Calcium Channels/metabolism , Calcium/metabolism , Coronary Artery Disease/enzymology , Membrane Proteins/metabolism , NADPH Oxidases/metabolism , Oxidative Stress , Coronary Vessels/enzymology , Endothelium/enzymology , Female , Humans , Male , Middle Aged , Myocytes, Smooth Muscle/enzymology , NADPH Oxidase 5 , Pilot Projects , RNA, Messenger , Reactive Oxygen Species/metabolism , Risk FactorsABSTRACT
OBJECTIVES: We sought to study the prognostic utility of coronary artery calcium (CAC) in the elderly. BACKGROUND: The prognostic significance of CAC in the elderly is not well known. METHODS: All-cause mortality was assessed in 35,388 patients (3,570 were >or=70 years old at screening, and 50% were women) after a mean follow-up of 5.8 +/- 3 years. RESULTS: In older patients, risk factors and CAC were more prevalent. Overall survival was 97.9% at the end of follow-up. Mortality increased with each age decile with a relative hazard of 1.09 (95% confidence interval: 1.08 to 1.10, p < 0.0001), and rates were greater for men than women (hazard ratio: 1.53; 95% confidence interval: 1.32 to 1.77, p < 0.0001). Increasing CAC scores were associated with decreasing survival across all age deciles (p < 0.0001). Survival for a <40-year and >or=80-year-old man with a CAC score >or=400 was 88% and 19% (95% and 44% for a woman, p < 0.0001), respectively. Among the 20,562 patients with no CAC, annual mortality rates ranged from 0.3% to 2.2% for patients age 40 to 49 years or >or=70 years (p < 0.0001). The use of CAC allowed us to reclassify more than 40% of the patients >or=70 years old more often by excluding risk (i.e., CAC <400) in those with >3 risk factors. CONCLUSIONS: Despite their limited life expectancy, the use of CAC discriminates mortality risk in the elderly. Furthermore, the use of CAC allows physicians to reclassify risk in the elderly.
Subject(s)
Calcinosis/mortality , Cardiomyopathies/mortality , Coronary Artery Disease/mortality , Adult , Age Distribution , Age Factors , Aged , Aged, 80 and over , Calcinosis/economics , Cardiomyopathies/economics , Coronary Artery Disease/economics , Cost-Benefit Analysis , Female , Humans , Male , Middle Aged , Odds Ratio , Predictive Value of Tests , Prognosis , Prospective Studies , Risk Assessment , Risk Factors , Severity of Illness Index , Sex Distribution , Sex Factors , Survival Analysis , Survival Rate , United States/epidemiologyABSTRACT
Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) is a member of the tumor necrosis factor superfamily. TWEAK acts via binding to a cell surface receptor named Fn14. To study the role of this cytokine in the regulation of the permeability of the neurovascular unit (NVU) during cerebral ischemia, TWEAK activity was inhibited in wild-type mice with a soluble Fn14-Fc decoy receptor administered either immediately or 1 h after middle cerebral artery occlusion (MCAO). Administration of Fn14-Fc decoy resulted in faster recovery of motor function and a 66.4%+/-10% decrease in Evans blue dye extravasation when treatment was administered immediately after MCAO and a 46.1%+/-13.1% decrease when animals were treated 1 h later (n=4, P<0.05). Genetic deficiency of Fn14 resulted in a 60%+/-12.8% decrease in the volume of the ischemic lesion (n=6, P<0.05), and a 87%+/-22% inhibition in Evans blue dye extravasation 48 h after the onset of the ischemic insult (n=6, P<0.005). Compared with control animals, treatment with Fn14-Fc decoy or genetic deficiency of Fn14 also resulted in a significant inhibition of nuclear factor-kappaB pathway activation, matrix metalloproteinase-9 activation and basement membrane laminin degradation after MCAO. These findings show that the cytokine TWEAK plays a role in the disruption of the structure of the NVU during cerebral ischemia and that TWEAK antagonism is a potential therapeutic strategy for acute cerebral ischemia.